

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Original) A polynucleotide shown by the nucleotide sequence set forth in SEQ ID NO: 1 in the sequence listing or by the complementary nucleotide sequence, or a polynucleotide encoding a protein shown by the amino acid sequence set forth in SEQ ID NO: 2 in the sequence listing, or a polynucleotide shown by the complementary nucleotide sequence of the polynucleotide.
2. (Original) A polynucleotide shown by the nucleotide sequence set forth in SEQ ID NO: 3 or SEQ ID NO: 5, in the sequence listing, or by the complementary nucleotide sequence, or a polynucleotide encoding a protein shown by the amino acid sequence set forth in SEQ ID NO: 4 or SEQ ID NO: 6 in the sequence listing, or a polynucleotide shown by the complementary nucleotide sequence of the polynucleotide.
3. (Original) A polynucleotide containing a polynucleotide shown by the nucleotide sequence set forth in SEQ ID NO: 3, in the sequence listing or by the complementary nucleotide sequence, or a polynucleotide containing a polynucleotide encoding a protein shown by the amino acid sequence set forth in SEQ ID NO: 4, in the sequence listing, or a polynucleotide shown by the complementary nucleotide sequence of the polynucleotide, wherein the polynucleotide encodes a protein that accelerates the activation of Cdc42.
4. (Currently amended) A polynucleotide shown by a nucleotide sequence having a homology of at least approximately 70% with the nucleotide sequence of the polynucleotide according to claim 1, ~~or claim 2~~, wherein the polynucleotide encodes a protein that accelerates

the activation of Cdc42.

5. (Currently amended) A polynucleotide with a mutation or an induced mutation, such as deletion, substitution, or addition of one or more nucleotides in the nucleotide sequence of the polynucleotide according to claim 1 ~~or claim 2~~, wherein the polynucleotide encodes a protein that accelerates the activation of Cdc42.

6. (Currently amended) A polynucleotide that hybridizes to the polynucleotide according to claim 1 ~~or claim 2~~ under stringent conditions, wherein the polynucleotide encodes a protein that accelerates the activation of Cdc42.

7. (Currently amended) A recombinant vector containing the polynucleotide according to ~~any one of claims 1 to 6~~ claim 1.

8. (Original) A transformant that has been transfected with the recombinant vector according to claim 7.

9. (Original) A transformant that has been transfected with the recombinant vector according to claim 7, and a recombinant vector containing a polynucleotide encoding Cdc42.

10. (Original) A protein shown by the amino acid sequence set forth in SEQ ID NO: 2, in the sequence listing.

11. (Original) A protein shown by the amino acid sequence set forth in SEQ ID NO: 4 or SEQ ID NO: 6, in the sequence listing.

12. (Currently amended) A protein encoded by the polynucleotide according to ~~any one of claims 3 to 6~~ claim 3.

13. (Currently amended)) A method of producing the protein according to ~~any one of claims 10 to 12~~ claim 10, comprising a step of culturing the transformant ~~according to claim 8 or claim 9~~ that has been transfected with a recombinant vector containing a polynucleotide shown by a

polynucleotide encoding a protein shown by the amino acid sequence set forth in SEQ ID NO: 2 in the sequence listing, or a polynucleotide shown by the complementary nucleotide sequence of the polynucleotide.

14. (Currently amended) An antibody that recognizes the protein according to ~~any one of claims 10 to 12~~ claim 10.

15. (Currently amended) A method of identifying a compound that inhibits the function of the proteins according to ~~any one of claims 10 to 12~~ claim 10, and/or the expression of the polynucleotides shown by a polynucleotide encoding a protein shown by the amino acid sequence set forth in SEQ ID NO: 2 in the sequence listing, or a polynucleotide shown by the complementary nucleotide sequence of the polynucleotide according to any one of claims 1 to 6, comprising detecting the presence, absence or change in the function and/or the expression under conditions where the interaction of a compound with the protein and/or the polynucleotide are allowed, and determining whether the compound inhibits the function of the protein and/or the expression of the polynucleotide.

16. (Original) The method according to claim 15, wherein the function of the protein is a function of binding to Cdc42 and/or a function of accelerating the activation of Cdc42.

17. (Currently amended) A method of identifying a compound that inhibits the function of the protein according to ~~any one of claims 10 to 12~~ claim 10 and/or the expression of ~~the a~~ polynucleotide shown by a polynucleotide encoding a protein shown by the amino acid sequence set forth in SEQ ID NO: 2 in the sequence listing, or a polynucleotide shown by the complementary nucleotide sequence of the polynucleotide according to any one of claims 1 to 6, comprising using at least one selected from the protein ~~proteins according to any one of claims 10 to 12, the polynucleotides~~ a polynucleotide shown by a polynucleotide encoding a protein

shown by the amino acid sequence set forth in SEQ ID NO: 2 in the sequence listing, or a polynucleotide shown by the complementary nucleotide sequence of the polynucleotide according to any one of claims 1 to 6, the a recombinant vector containing said polynucleotide, according to claim 7, the transformants according to claim 8 or claim 9 a transformant that has been transfected with the recombinant vector or an and the antibody according to claim 14 that recognizes said protein.

18. (Original) The method according to claim 17, wherein the function of the proteins is a function of binding to Cdc42 and/or a function of accelerating the activation of Cdc42.

19. (Currently amended) A method of determining whether a tissue specimen derived from a human stomach tissue is a tissue derived from a human stomach tumor or not, comprising measuring an amount of expression of the polynucleotide according to ~~any one of claims 1 to 6~~ claim 1 in the tissue specimen.

20. (Currently amended) The method according to claim 19, wherein the method determines that the tissue specimen is a tissue derived from a human stomach tumor in the case when the amount of expression of the polynucleotide according to ~~any one of claims 1 to 6~~ claim 1 in the tissue specimen is 4.5 times higher than that in a control tissue derived from normal human stomach tissue.

21. (Currently amended) An agent for preventing and/or treating a stomach tumor, comprising a compound that inhibits the function of the protein according to ~~any one of claims 10 to 12~~ claim 10 and/or a compound that inhibits the expression of the polynucleotide shown by a polynucleotide encoding a protein shown by the amino acid sequence set forth in SEQ ID NO: 2 in the sequence listing, or a polynucleotide shown by the complementary nucleotide sequence of the polynucleotide according to any one of claims 1 to 6, as an effective ingredient.

22. (Currently amended) A method of preventing and/or treating a stomach tumor, comprising using a compound that inhibits the function of the protein according to ~~any one of claims 10 to 12~~ claim 10 and/or a compound that inhibits the expression of the polynucleotide shown by a polynucleotide encoding a protein shown by the amino acid sequence set forth in SEQ ID NO: 2 in the sequence listing, or a polynucleotide shown by the complementary nucleotide sequence of the polynucleotide ~~according to any one of claims 1 to 6.~~

23. (Currently amended) A reagent kit containing at least one selected from the protein according to ~~any one of claims 10 to 12~~ claim 10, ~~the~~ a polynucleotide shown by a polynucleotide encoding a protein shown by the amino acid sequence set forth in SEQ ID NO: 2 in the sequence listing, or a polynucleotide shown by the complementary nucleotide sequence of the polynucleotide ~~according to any one of claims 1 to 6, the~~ a recombinant vector containing said polynucleotide ~~according to claim 7, the~~ a transformant that has been transfected with the recombinant vector ~~according to claim 8 or claim 9, and the~~ or an antibody ~~according to claim 14 that recognizes said protein.~~